0000899243-18-029542.txt : 20181121
0000899243-18-029542.hdr.sgml : 20181121
20181121160554
ACCESSION NUMBER: 0000899243-18-029542
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181119
FILED AS OF DATE: 20181121
DATE AS OF CHANGE: 20181121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Barrowcliffe Susan E.
CENTRAL INDEX KEY: 0001664251
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 181198254
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD, SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-11-19
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001664251
Barrowcliffe Susan E.
AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
0
1
0
0
General Manager, Europe
Common Stock, $0.0001 par value
2018-11-19
4
M
0
40000
3.022
A
49375
D
Common Stock, $0.0001 par value
2018-11-19
4
S
0
40000
30.04
D
9375
D
Stock Option (right to buy)
3.022
2018-11-19
4
M
0
40000
0.00
D
2025-05-13
Common Stock
40000
53400
D
Includes restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
The option is immediately exercisable in full or in part. The underlying shares vest pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vest on the first anniversary measured from May 1, 2015 (the "Vesting Commencement Date") and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Susan E. Barrowcliffe
2018-11-21